Investor Presentation Q1-Q3 2020
121
Investor presentation
First nine months of 2020
Novo Nordisk offers affordability programmes to increase
support to patients inside and outside the system
Continue
offering
Opera-
tionalise
Increase support for patients inside the
insurance system
Supporting Affordable Patient Access
~USD18 billion in access rebates, discounts and fees¹
>USD200 million in co-pay assistance programmes¹
Follow-on brand
insulin²
List price discount of
50% of NovoLogⓇ and
NovoLog® Mix
Safety net for those
patients inside and
outside the system
IRS Preventive Benefit
Change
.
Timing: Immediate, impact
starting 2021
CIGNA/ESI partnering on
benefit design
Expand support for patients outside
the system
Patient Assistance Program
PAP: ~50,000 patients receive free insulin¹
• Added Ozempic®, XultophyⓇ and Rybelsus®
Insulin Savings Programme²
.
.
USD99 for up to 3 vials or 2 boxes of pens
Any combination of NNI analog insulins
Affordable Human Insulin Option²
Novo Nordisk human insulin available for about USD25/vial at national pharmacies, including
Walmart and CVS
An estimated 500,000 accessing Novo Nordisk human insulin through these partnerships
An immediate, one-time insulin supply option available for people facing acute need
1 Based on full year 2010 numbers; 2 Available from Novo Nordisk Pharma, Inc., a Novo Nordisk A/S company
2 Initiatives effective as of January 2020
Novo NordiskⓇView entire presentation